Insights

Drs Regueiro and Siegel review their debate from the Advances in Inflammatory Bowel DIseases 2022 annual meeting about if, when, and how to stop or de-escalate therapy for IBD.

Dr Sands, from the Icahn School of Medicine at Mt Sinai in New York, discusses the results from the QUASAR study of guselkumab in ulcerative colitis, in which nonresponding patients received subcutaneous drug over an additional 12 weeks to...

Dr Sands provides an overview of the VEGA study, the first of its kind to combine 2 biologic agents to attempt to achieve higher rates of remission among patients with ulcerative colitis.

Dr Melmed, from Cedars-Sinai in Los Angeles, discusses neurological complications that may arise among patients being treated for inflammatory bowel disease--and what clinicians should watch for to prevent or mitigate them.

Dr Regueiro, from Cleveland Clinic, reviews the armamentarium of therapies available today for inflammatory bowel diseases and how best to position them to optimize outcomes among patients.

Dr Rubin, from the University of Chicago, explains key points from his presentation at AIBD 2022 on risks of colon cancer among patients with inflammatory bowel disease and how to best monitor for dysplasia and mitigate risks.

Dr Moss, from Boston University School of Medicine, discusses his presentation on defining severity of inflammatory bowel disease, including differences in patient and physician perceptions.

Dr Dubinsky, from the Icahn School of Medicine at Mount Sinai in New York City, reviews her keynote presentation on the use of newer biologics with pediatric patients with inflammatory bowel diseases.